Immutep Limited

Healthcare · Biotechnology · Australia

Last price 3.06 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 23.85M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb...